Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on AUPH stock, giving a Buy rating on August 2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Schwartz has given his Buy rating due to a combination of factors including Aurinia Pharmaceuticals’ strong financial performance and promising pipeline developments. The company reported impressive net product sales of $66.6 million for Lupkynis in the second quarter of 2025, surpassing both the firm’s and consensus estimates. This robust performance led to an upward revision of the full-year sales guidance, indicating confidence in continued growth.
Additionally, Aurinia is making significant progress in its pipeline, particularly with the planned clinical studies of aritinercept in autoimmune diseases. The positive first-in-human data for aritinercept suggests potential for once-monthly dosing, aligning with industry standards. The company’s healthy cash position and strategic share repurchase plan further reinforce its financial stability and shareholder value, supporting Schwartz’s optimistic outlook.
In another report released on August 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $12.00 price target.